Aurobindo Pharma (AUROPHARMA) | Stock Overview & Key Data
Aurobindo Pharma Performance Comparison
Stock Range
Today's Range
52 Week Range
All-Time High: ₹1,592.00 on September 9, 2024
Explore how other Indian stocks compare to their 52-week ranges: View IN Market 52-Week Insights
Key Statistics
Join Our India Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Financial Highlights
Quarter Income Flow
Jun 30, 2025
Annual Income Flow
2025
Dividend Information
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Aurobindo Pharma
AUROPHARMA
|
833.68B Large-cap | -3.00% | -6.85% | 10.06% | 18.71% | 18.05% | 28.05% | 115.76% | 54.63% | 102.36% | 1,590.54% | 2,949.28% |
|
Sun Pharmaceutical
SUNPHARMA
|
3.88T Large-cap | 0.96% | -3.84% | 1.28% | 0.50% | 4.93% | 7.10% | 82.23% | 170.41% | 143.23% | 656.74% | 2,541.29% |
|
Divi's Laboratories
DIVISLAB
|
1.69T Large-cap | 1.34% | -2.25% | 8.85% | 4.11% | 4.17% | -0.43% | 85.44% | 58.15% | 496.33% | 1,610.60% | 10,946.76% |
|
Torrent
TORNTPHARM
|
1.39T Large-cap | 2.12% | 2.23% | 5.56% | 19.07% | 17.04% | 40.54% | 146.00% | 215.51% | 578.42% | 2,737.14% | 10,046.95% |
|
Dr. Reddy's
DRREDDY
|
1.10T Large-cap | 0.31% | -4.28% | 0.20% | -0.09% | 2.08% | -6.39% | 29.74% | 20.69% | 112.36% | 310.53% | 902.28% |
|
Lupin
LUPIN
|
1.07T Large-cap | 0.83% | -0.14% | -0.76% | 8.63% | 8.10% | 14.69% | 176.15% | 98.45% | 56.65% | 418.49% | 2,332.69% |
Ownership & Short Interest
Calculate Your Aurobindo Pharma Investment Returns
Long-Term Investment Performance Analysis
Aurobindo Pharma stock price in Jul 2016 was ₹798.55, A ₹1,000.00 lump sum investment in Aurobindo Pharma made 9 years ago would be worth approximately ₹1,763.57 today, representing a solid return of 76.36%. This translates to an annualized return (CAGR) of 5.89%.
9 Years 10 Months Investment Scenario (Jul 2016 - Jun 2026)
Investment Breakdown
Value Comparison
Disclaimer: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing. Past performance does not guarantee future results.
Frequently Asked Questions
- What is AUROPHARMA's 52-week high and low?
- In the last 52 weeks, Aurobindo Pharma reached a high of ₹1,550.00 (on May 21, 2026) and a low of ₹1,016.10 (on September 1, 2025).
- What is the market cap and P/E ratio for AUROPHARMA?
- Curious about Aurobindo Pharma's size and valuation? Its market capitalization stands at 833.68B. When it comes to valuation, the P/E ratio (trailing twelve months) is 23.69, and the forward P/E (looking ahead) is 18.60.
- Does AUROPHARMA pay dividends? If so, what's the yield?
- Yes, Aurobindo Pharma is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 0.38%, and the company has paid an average of ₹3.83 per share annually over the past 3 years.
- Who are Aurobindo Pharma's main competitors or similar companies to consider before investing?
When looking at Aurobindo Pharma, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Sun Pharmaceutical
SUNPHARMA3.88T Healthcare Drug Manufacturers - Specialty & Generic 7.10% 82.23% Divi's Laboratories
DIVISLAB1.69T Healthcare Drug Manufacturers - Specialty & Generic -0.43% 85.44% Torrent
TORNTPHARM1.39T Healthcare Drug Manufacturers - Specialty & Generic 40.54% 146.00% Dr. Reddy's
DRREDDY1.10T Healthcare Drug Manufacturers - Specialty & Generic -6.39% 29.74% Lupin
LUPIN1.07T Healthcare Drug Manufacturers - Specialty & Generic 14.69% 176.15% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Aurobindo Pharma Ltd.? (e.g., ROE, Debt/Equity)
- To get a sense of Aurobindo Pharma's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 10.68%, the Debt to Equity ratio from the most recent quarter is 22.25, and its Gross Profit Margin stands at 59.54%.
- What is the recent revenue and earnings growth for AUROPHARMA?
- Looking at Aurobindo Pharma's growth, its revenue over the trailing twelve months (TTM) was INR332B. Compared to the same quarter last year (YoY), quarterly revenue grew by 8.40%, and quarterly earnings saw a YoY growth of 7.60%.
- How much of AUROPHARMA stock is held by insiders and institutions?
- Wondering who owns Aurobindo Pharma stock? Company insiders (like executives and directors) hold about 54.20% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 28.78%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.